PDL BioPharma, Inc. PDLI

Other — Other

Market cap: —
P/E: 0.0×

Follow PDLI

Overview Business Profile Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions

in millions of $

	Nov 25			Feb 26			May 26			Aug 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 32.99%

Capital & Financial Ratios

Market Cap —

Revenue 51.81

Net Income (137.17)

Free Cash Flow (6.85)

Net Debt (91.94)

Current Ratio 13.68

Debt/Equity 0.03

P/E ratio 0.00

P/S ratio 5.53

P/B ratio 0.68

Past 5Y EPS Growth —

This Y EPS Growth —

Next Y EPS Growth —

Next 5Y EPS Growth —

in millions of $

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

	2017	2018	2019	Q'20
Cash	532	395	193	105
Receivables	31	22	14	6
Inventory	9	19	40	13
Other	—	—	—	289
	640	517	314	496

	2017	2018	2019	Q'20
Payables	20	13	17	4
ST’ Debt	—	—	—	—
Other	—	—	—	18
	193	52	46	36

in millions of $

Compound Annual Growth

	10y	5y	3y
Sales	(16.14%)	(37.65%)	(39.26%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	5.20%	(7.74%)

Revenue

	Mar	Jun	Sep	Dec	Year
’26	6	5	—	—	—
’19	7	7	44	—	55
’18	39	47	68	45	198
’17	45	144	63	68	320

in millions of $ · fiscal quarters ending in the months shown

value withheld pending a data check

Operating Cash Flow

	Mar	Jun	Sep	Dec	Year
’26	(15)	(20)	—	—	—
’19	(2)	23	(34)	(19)	(32)
’18	(14)	(6)	8	(2)	(13)
’17	46	16	(4)	(17)	41

in millions of $ · fiscal quarters ending in the months shown

Free Cash Flow

	Mar	Jun	Sep	Dec	Year
’26	(15)	(20)	—	—	—
’19	(2)	21	29	2	49
’18	(15)	29	7	19	40
’17	67	42	22	15	147

in millions of $ · fiscal quarters ending in the months shown

EPS

	Mar	Jun	Sep	Dec	Year
’26	(0.26)	(0.43)	—	—	—
’19	0.05	(0.04)	(0.16)	(0.48)	(0.59)
’18	0.01	(0.76)	0.18	0.11	(0.47)
’17	0.04	0.39	0.14	0.15	0.71

fiscal quarters ending in the months shown

2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021
—	—	—	—	—	—	—	—	—	—	Analyst estimates 2021–2023 Powerpack	Low Price
—	—	—	—	—	—	—	—	—	—		High Price
—	—	—	—	—	11	87	20	75	11		Employees
—	—	—	—	—	22	4	10	1	0		Revenue/Emp
—	—	—	—	—	244	320	198	55	—		Revenue
—	—	—	—	—	98.34%	90.46%	75.54%	2.08%	—		Gross Margin
—	—	—	—	—	109	185	(56)	(74)	—		EBT
—	—	—	—	—	44.77%	57.65%	(28.23%)	(134.67%)	—		EBT Margin
—	—	—	—	—	64	111	(69)	(71)	0		Net Income
—	—	—	—	—	22	38	27	17	—		Depreciation
—	—	—	—	—	1.49	2.06	1.36	0.46	—		Revenue/Sh
—	—	—	—	—	0.39	0.71	(0.47)	(0.59)	—		Earnings/Sh
—	—	—	—	—	0.62	0.26	(0.09)	(0.27)	—		Cash Flow/Sh
—	—	—	—	—	0.08	0.68	0.37	0.69	—		Capex/Sh
—	—	—	—	—	0.70	0.94	0.27	0.42	—		Free CF/Sh
—	—	—	—	—	4.61	5.44	5.01	5.00	—		Book Value/Sh
—	—	—	—	—	164	155	146	119	—		Shares
—	—	—	—	—	5.72	3.99	0.00	0.00	—		PE Ratio
—	—	—	—	—	1.50	1.39	2.13	7.04	—		PS Ratio
—	—	—	—	—	0.48	0.53	0.58	0.65	—		PB Ratio
—	—	—	—	—	1.46	0.10	0.77	4.45	—		EV/Sales
—	—	—	—	—	3.10	0.21	2.09	3.47	—		EV/FCF
—	—	—	—	—	102	41	(13)	(32)	—		Op' Cash Flow
—	—	—	—	—	13	106	53	82	—		Capex
—	—	—	—	—	115	147	40	49	—		FCF
—	—	—	—	—	268	447	465	268	—		Working Cap'
—	—	—	—	—	232	117	125	27	—		Total Debt
—	—	—	—	—	(10)	(415)	(270)	(166)	—		Net Debt
—	—	—	—	—	755	846	730	593	—		Sh' Equity
—	—	—	—	—	5.71%	9.01%	(6.24%)	(8.38%)	0.00%		ROA
—	—	—	—	—	10.85%	28.09%	(6.88%)	(14.61%)	—		ROIC
—	—	—	—	—	8.76%	13.83%	(8.74%)	(10.64%)	—		ROE

predictions in italic, sparklines do not include predictions

All 10 years →

Fiscal years to Dec 2019 · latest quarter Jun 2020